HIND Vyome Therapeutics: Forward Price-to-Revenue Multiple

Vyome Holdings Inc (HIND) - corporate logo

The forward P/S ratio of Vyome Holdings Inc (HIND) reflects the sales valuation trend, with the indicator currently standing at 72.70. The Vyome Holdings Inc (HIND) team is recruiting immunology and weight loss experts through the expansion of R&D. Revenue is driven by the implementation of Lap-Band systems and new pharmaceuticals, although financial stability requires strict oversight due to asset restructuring.

HIND (Vyome Holdings) Market Cap to Future Revenue Ratio history from 08/16/2025 to 11/18/2026

Summary analytical data breakdowns for Vyome Holdings Inc (HIND)

- current price and projected stock value:
Initial company analysis:ReShape Lifesciences (HIND)
Original product of Vyome Therapeutics

For Vyome Holdings Inc (HIND), the potential of the DART platform in treating resistant infections determines the market value of future revenue streams, making a valuation based on forward P/S critically important. By analyzing the forward P/S dynamics, an investor can see the ratio of current market capitalization to projected sales, which allows for the identification of asset overvaluation or the discovery of an entry point when expected revenue is undervalued.

Key competitors

Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Biosciences)|Market Cap to Expected Sales Ratio theratech.com|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc.)|Forward P/S Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio, Inc)|ZURA: Forward P/S Multiple|aTyr Pharma, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Adagene Inc.|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Forward Price-to-Revenue Multiple Equillium Bio EQ|Price-to-Projected Revenue Ratio Connect Biopharma CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx NV (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Adicet Bio Inc. (ACET)|Price-to-Projected Revenue Ratio celularity.com|Forward Price-to-Revenue Multiple inmunebio.com (INMB)|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics PLC (BRNS)|Market Cap to Expected Sales Ratio Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Akari Therapeutics, Plc (AKTX)|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Edesa|Price-to-Projected Revenue Ratio iBio, Inc.|Forward Price-to-Revenue Multiple carismatx.com (CARM)|Forward P/S Multiple XTLB|Forward Price-to-Revenue Multiple Bolt Bio BOLT|Forward P/S Multiple HCWB (HCW Biologics)|APVO: Market Cap to Projected Revenue|AIM - Price-to-Projected Revenue Ratio|ADTX - Forward P/S Multiple|GRI Bio (GRI) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple XORTX Therapeutics|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com